3 unknown, 2 completed. 2 Phase 2, 2 Phase 4, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 4 | 2 | Unknown 2 |
| Phase 1 | 1 | Unknown 1 |
Follow Dermatomyositis, Adult Type: new trials by email Literature Review of Dermatomyositis, Adult Type trials Research Report on Dermatomyositis, Adult Type
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis Brepocitinib - Dermatomyositis, Dermatomyositis, Adult Type | Phase 2 | Completed | Priovant Therapeutics, Inc. | 5 | 2024-08-28 | 2025-05-20 |
| Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis Itolizumab - Dermatomyositis, Adult Type | Phase 1 | Unknown | Biotech Pharmaceutical Co., Ltd. | 44 | 2023-12-30 | 2023-08-14 |
| Efficacy and Safety of Triple Therapy in Patients With Anti-MDA5 Antibody-positive Dermatomyositis triple therapy, dual-therapy - Dermatomyositis, Adult Type, Interstitial Lung Disease | Phase 4 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 120 | 2022-01-01 | 2022-05-26 |
| The Efficacy and Safety of JAK Inhibitor in the Treatment of Anti-MDA5 Antibody-positive Dermatomyositis Patients JAK Inhibitor - Dermatomyositis, Adult Type | Phase 4 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 20 | 2020-04-02 | 2021-07-19 |
| Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis Apremilast 30mg - Dermatomyositis, Adult Type | Phase 2 | Completed | Tulane University | 8 | 2018-06-12 | 2023-03-03 |
Dermatomyositis (5) · Lung Diseases, Interstitial (1)
Connective Tissue Diseases (5) · Muscular Diseases (5) · Musculoskeletal Diseases (5) · Myositis (5) · Nervous System Diseases (5) · Neuromuscular Diseases (5) · Polymyositis (5) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Lung Diseases (1) · Respiratory Tract Diseases (1)
Dual Anti-Platelet Therapy (1) · Janus Kinase Inhibitors (1) · apremilast (1) · itolizumab (1)
Biotech Pharmaceutical Co., Ltd. (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · Priovant Therapeutics, Inc. (1) · The First Affiliated Hospital with Nanjing Medical University (1) · Tulane University (1)
China (2) · United States (2)
Carole Bitar, MD (1) · Lan He (1) · Rui Chen (1) · Xiaofeng Zeng (1)
PMID 29229575, PMID 30060040, PMID 31314977, PMID 31375890, PMID 36197661